Cargando…
Carbonic Anhydrase IX: A Renewed Target for Cancer Immunotherapy
SIMPLE SUMMARY: Carbonic anhydrase IX (CAIX) has been explored for a long time as a therapeutic target in the fight against clear cell renal cell carcinoma and several hypoxic tumors, usually offering modest results followed by adverse effects. However, recent studies using different antibodies and...
Autores principales: | de Campos, Najla Santos Pacheco, Souza, Bruna Santos, da Silva, Giselle Correia Próspero, Porto, Victoria Alves, Chalbatani, Ghanbar Mahmoodi, Lagreca, Gabriela, Janji, Bassam, Suarez, Eloah Rabello |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946730/ https://www.ncbi.nlm.nih.gov/pubmed/35326544 http://dx.doi.org/10.3390/cancers14061392 |
Ejemplares similares
-
Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells
por: de Campos, Najla Santos Pacheco, et al.
Publicado: (2022) -
CAR-T cells: Early successes in blood cancer and challenges in solid tumors
por: Dana, Hassan, et al.
Publicado: (2021) -
Renewed interests in carbonic anhydrase IX in relevance to breast cancer treatment
por: Dolatkhah, Mitra, et al.
Publicado: (2019) -
Carbonic anhydrase IX in oligodendroglial brain tumors
por: Järvelä, Sally, et al.
Publicado: (2008) -
Targeting Carbonic Anhydrase IX Activity and Expression
por: Mahon, Brian P., et al.
Publicado: (2015)